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Summary  The  discovery  of  angiotensin-I-converting  enzyme  2  (ACE2)  and  a  (pro)renin  recep-
tor has  renewed  interest  in  the  physiology  of  the  renin-angiotensin  system  (RAS).  Through
the ACE2/angiotensin-(1—7)/Mas  counter-regulatory  axis,  ACE2  balances  the  vasoconstrictive,
proliferative,  ﬁbrotic  and  proinﬂammatory  effects  of  the  ACE/angiotensin  II/AT1  axis.  The
(pro)renin  receptor  system  shows  an  angiotensin-dependent  function  related  to  increased
generation of  angiotensin  I,  and  an  angiotensin-independent  aspect  related  to  intracellular
signalling.  Activation  of  ACE2  and  inhibition  of  ACE  and  renin  have  been  at  the  core  of  the  RAS
regulation. The  aim  of  this  review  is  to  discuss  the  biochemistry  and  biological  functions  of  ACE,
ACE2 and  renin  within  and  beyond  the  RAS,  and  thus  provide  a  perspective  for  future  bioactives
from natural  plant  and/or  food  resources  related  to  the  three  proteases.
© 2012  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé  La  découverte  de  l’enzyme  de  conversion  de  l’angiotensine  2  (AC2)  et  un  récepteur
à la  prorénine  est  une  avancée  récente  dans  la  compréhension  de  la  physiologie  du  système
rénine-angiotensine.  Au  sein  de  l’axe  inhibiteur  de  l’enzyme  de  conversion  de  l’angiotensine
2/angiotensine  1/MAS,  l’AC2  contrebalance  l’effet  vasoconstricteur,  prolifératif,  ﬁbrosant  et
pro-inﬂammatoire  de  l’axe  ACE/angiotensine  2/AT1.  Le  récepteur  à  la  prorénine  a  une  fonc-
tion angiotensine  dépendante,  liée  à  l’augmentation  de  la  production  d’angiotensine  1,  et  un
aspect indépendant  de  l’angiotensine,  lié  aux  signaux  intracellulaires.  L’activation  de  l’AC2  et
l’inhibition  de  l’ACE  de  la  rénine  ont  été  considérées  comme  au  centre  de  la  régulation  du
système rénine-angiotensine.  L’objet  de  cette  revue  générale  est  de  discuter  les  fonctions
biochimiques  et  biologiques  de  l’ACE,  de  l’AC2  et  de  la  rénine  au  sein  et  au-delà  du  système
rénine-angiotensine  et  ainsi  de  proposer  une  perspective  de  développement  d’agents  actifs
extraits de  plantes  naturelles  ou  d’alimentation,  produits  liés  à  ces  trois  protéases.
© 2012  Elsevier  Masson  SAS.  Tous  droits  réservés.
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he  renin-angiotensin  system  (RAS)  is  not  only  an  endocrine
ut  also  a  paracrine  and  an  intracrine  system  [1].  In  mam-
als,  the  intravascular  RAS  plays  a  key  role  in  maintaining
lood  pressure  homeostasis  and  ﬂuid  and  salt  balance,  and
he  tissue  or  local  RAS  is  involved  in  physiological  and  patho-
ogical  processes,  such  as  tissue  growth  and  remodelling,
evelopment  and  inﬂammation  [2].  In  a  classical  RAS,  the
ubstrate  angiotensinogen  (AGT),  which  is  released  into
he  circulation  from  the  liver,  is  degraded  by  the  enzyme
enin  that  originates  in  the  kidney,  generating  the  inactive
ngiotensin  I  (Ang  I).  When  this  decapeptide  comes  into
ontact  with  angiotensin-I-converting  enzyme  (ACE)  at  the
ndothelial  surface  of  blood  vessels,  the  C-terminal  dipep-
ide  is  cleaved,  giving  rise  to  angiotensin  II  (Ang  II),  the  main
ffector  molecule  of  the  RAS.  Through  interactions  with  spe-
iﬁc  receptors,  particularly  its  type  1  or  AT1  receptor,  Ang  II
timulates  a  wide  variety  of  signalling  pathways  in  the  heart,
lood  vessels,  kidneys,  adipose  tissue,  pancreas  and  brain,
nitiating  most  of  the  physiological  and  pathophysiological
ffects  that  have  been  attributed  to  the  RAS  [3].  Due  to  the
unction  of  directly  generating  the  main  effector  Ang  II,  ACE
 together  with  the  classical  axis  ACE/Ang  II/AT1  —  has  been
t  the  core  of  RAS  studies  since  its  discovery.
In  2000,  a  homologue  of  ACE,  known  as  angiotensin-I-
onverting  enzyme  2  (ACE2),  was  cloned  by  two  independent
esearch  groups  [4,5]. Evidence  indicates  that  ACE2  nega-
ively  regulates  the  activated  RAS  by  degrading  Ang  II  to
he  heptapeptide  Ang-(1—7).  Moreover,  through  the  Mas
eceptor  (a  G  protein-coupled  receptor),  the  resulting  Ang-
1—7)  counterbalances  the  cardiovascular  effects  of  Ang  II
y  opposing  many  AT1  receptor-mediated  actions  [6].  ACE2
nd  the  axis  ACE2/Ang-(1—7)/Mas  are  becoming  the  focus
f  intense  research  regarding  the  RAS  [1].  The  discovery
f  a  (pro)renin  receptor  ([P]RR)  and  the  introduction  of
enin  inhibitors  have  also  brought  (pro)renin  back  into  the
potlight  [7].  Far  from  being  a  straightforward  cascade  con-
aining  one  substrate  (AGT),  two  proteases  (renin  and  ACE),
wo  peptides  (Ang  I  and  Ang  II)  and  one  receptor  (AT1),  the
AS  currently  consists  of  several  axes  upstream  and  down-
tream  of  the  classical  cascade,  which  include  more  than
wo  dozen  peptidases,  nearly  a  dozen  Ang  fragments  and
d
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ht  least  six  different  receptors  [8].  Here,  we  review  three
ritical  proteases  (ACE,  ACE2  and  renin)  within  and  beyond
he  RAS  and  thus  intend  to  ﬁnd  new  connections  between
atural  plant  and/or  food  resources  and  the  RAS.
ccurrence, gene encoding and structure
f  ACE
CE  (EC  3.4.15.1)  is  a  monomeric  glycoprotein  that  is  dis-
ributed  in  many  tissues  and  biological  ﬂuids.  There  are  two
soforms  of  ACE  in  humans:  somatic  ACE  (sACE)  and  ger-
inal  ACE  (gACE).  Somatic  ACE  is  found  in  many  types  of
ndothelial  and  epithelial  cells  [9].  Germinal  ACE  or  testic-
lar  ACE  is  present  exclusively  in  germinal  cells  in  the  male
estis.  Although  ACE  is  a  type  I  integral  membrane  protein,
t  can  also  be  released  as  a  soluble  enzyme  into  extracel-
ular  ﬂuids,  such  as  plasma  and  seminal  and  cerebrospinal
uids,  following  post-translational  proteolytic  cleavage  by  a
embrane  protein  sheddase  or  secretase  [10—12].
Somatic  ACE  and  gACE  are  encoded  by  a  single  gene  con-
aining  26  exons.  The  promoter  for  sACE  is  situated  in  the
′ ﬂanking  region  of  the  ﬁrst  exon,  whereas  that  for  gACE
s  within  intron  12,  which  results  in  different  lengths  for
he  two  isoforms.  The  longer  sACE  (150—180  kDa)  is  tran-
cribed  from  exon  1  to  exon  26,  excluding  exon  13,  whereas
he  shorter  gACE  (90—110  kDa)  is  transcribed  from  exon  13
o  exon  26.  Exon  13  encodes  a  unique  sequence  for  the
-terminus  of  gACE,  whereas  downstream  exons  encode  a
ommon  sequence  for  both  isozymes  [13].
Somatic  ACE  and  gACE  both  consist  of  a  28-residue
ydrophilic  C-terminal  cytoplasmic  domain,  a  22-residue
ydrophobic  transmembrane  domain  that  anchors  the  pro-
ein  in  the  membrane  and  an  N-terminal  ectodomain
Fig.  1)  that  is  heavily  glycosylated  with  mannose,  galactose,
ructose,  N-acetylneuraminic  acid  and  N-acetylglucosamine
14].  The  ectodomain  of  sACE  is  further  divided  into  two
imilar  domains  (N  domain  and  C  domain)  encoded  by  the
omologous  exons  4—11  and  17—24,  respectively,  and  each
omain  contains  an  active  His-Glu-X-X-His  (HEXXH)  sequence
9].  Somatic  ACE  is  the  only  known  metallopeptidase  with
wo  homologous  active  sites  [15], which  implies  that  there
as  been  a  gene  duplication  event  during  evolution  [16].
ACE,  ACE2  and  renin  
Figure 1. Schematic representation of the primary structures
of sACE, gACE, ACE2 and collectrin [6].  ACE: angiotensin-I-
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tion  of  sodium  and  water.  These  effects  act  directly  inconverting enzyme; gACE: germinal ACE; HEXXH: His-Glu-X-X-His;
sACE: somatic ACE.
Except  for  a  unique  sequence  constituting  its  N-terminus,
gACE  is  identical  to  the  C-terminal  half  of  sACE  [17]. Due
to  cleavage  of  the  membrane-bound  residues  by  ACE  secre-
tase,  soluble  circulating  ACE  lacks  a  transmembrane  portion
and  a  cytosolic  domain  [18].
The  three-dimensional  X-ray  crystallographic  structure
of  a  deglycosylated  truncated  version  of  gACE  (C  domain
of  sACE),  reveals  a  preponderance  of  -helices  with  a  zinc
ion  and  two  chloride  ions  incorporated.  A  deep  narrow
channel  separates  the  molecule  into  two  subdomains  and
the  active  site  is  located  toward  the  bottom  of  this  chan-
nel.  An  N-terminal  ‘lid’  on  the  top  of  molecule  appears  to
allow  only  small  peptide  substrates  access  to  the  active
site  cleft.  In  fact,  the  structure  bears  little  similarity  to
that  of  carboxypeptidase  A  (M14  family)  on  which  the  ini-
tial  drug  development  of  ACE  inhibitors  was  based.  Instead,
it  resembles  rat  neurolysin  (M3  family)  and  Pyrococcus  furio-
sus  carboxypeptidase  (M32  family),  despite  sharing  little
sequence  similarity  with  these  two  proteins  [17]. Corradi
et  al.  [18]  reported  the  crystal  structure  of  the  N  domain
of  sACE.  Similarly,  it  has  an  ellipsoid  shape  with  a  central
groove  dividing  it  into  two  subdomains,  one  of  which  con-
tains  the  N-terminal  region  that  covers  the  central  binding
cavity.  But  the  structure  reveals  differences  in  the  active
site  and  it  contains  only  one  chloride  ion,  equivalent  to
chloride  II  of  gACE.  The  three-dimensional  structures  of  C
domains  (based  on  gACE)  and  N  domains  provide  an  oppor-
tunity  to  design  domain-selective  ACE  inhibitors  that  may
exhibit  new  pharmacological  proﬁles  [17,18].
Catalytic mechanism of ACE
According  to  the  catalytic  mechanism  and  the  critical  amino
acid  residue  involved,  peptidases  are  classiﬁed  into  four
major  types:  serine,  cysteine,  aspartic  and  metallo  [15]. ACE
is  an  M2  family  metallopeptidase:  MA(E),  the  gluzincins  [19].
Two  histidine  residues  of  the  functional  motif  HEXXH  and  a
third  distant  glutamate  positioned  23—24  residues  further
towards  the  C-terminus  are  the  ligands  for  the  zinc  cofac-
tor  [20]. An  activated  water  molecule  complexed  to  Zn2+
serves  as  the  nucleophile  to  attack  the  carbonyl  group  of
the  targeted  peptide  bond  [15].
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The activity  of  ACE  is  also  chloride  dependent.  Chloride
rimarily  activates  the  active  sites  of  ACE  and  enhances  the
inding  of  substrates  [9].  Each  active  domain  of  ACE  dis-
lays  differences  in  sensitivity  to  chloride  activation  [21].
he  activity  of  the  C  domain  of  sACE  depends  highly  on  chlo-
ide  ion  concentration  and  is  inactive  in  its  absence,  whereas
he  N  domain  can  be  completely  activated  at  relatively  low
oncentrations  of  this  anion  and  is  still  active  in  the  absence
f  chloride  [22,23]. Germinal  ACE  depends  on  chloride  to
 lesser  extent  compared  with  the  C  domain  of  sACE  [9].
ushman  and  Cheung  [24]  reported  an  optimal  in  vitro  ACE
ctivity  of  rabbit  rung  acetone  extract  in  the  presence  of
00  mM  NaCl  at  pH  8.1—8.3.
The  two  active  domains  of  sACE  are  also  subtly  different
n  substrate  speciﬁcity.  They  hydrolyze  bradykinin  almost
qually  but  the  C  domain  active  site  can  hydrolyze  Ang  I,
ubstrate  P  [23]  and  Hippuryl-His-Leu  [25]  more  efﬁciently,
hile  the  N  domain  active  site  preferentially  hydrolyzes  Ang-
1—7)  [26], luteinizing  hormone-releasing  hormone  (LH-RH)
23],  the  haemoregulatory  peptide  N-acetyl-Ser-Asp-Lys-Pro
AcSDKP)  [27]  and  Alzheimer  amyloid  -peptide  (A)  [28].
uchs  et  al.  [29]  proved  that  the  C-terminal  catalytic  domain
as  the  main  site  of  Ang  I  cleavage  in  mice.  The  differen-
iation  of  catalytic  speciﬁcity  might  be  due  to  very  subtle
ariation  in  substrate-speciﬁc  amino  acids  [22]  and  chloride-
nduced  conformational  alteration  of  active  sites  [23].
ACE  acts  as  an  exopeptidase  to  cleave  dipeptides  from
he  free  C-termini  of  two  typical  substrates,  Ang  I  and
radykinin.  For  certain  substrates  such  as  cholecystokinin
30],  substrate  P  [31]  and  LH-RH  [32], which  have  amidated
-termini,  ACE  not  only  displays  exopeptidase  activity  but
lso  acts  as  an  endopeptidase  [33]. The  most  prominent
xample  of  endopeptidase  activity  is  ACE  hydrolyzing  the
ynthetic  A-(1—40)  peptide  into  four  fragments:  an  A-
8—40)  peptide  and  the  others  corresponding  to  products
f  A-(1—7)  hydrolysis  [34]. Thus,  ACE  might  have  a  more
eneral  impact  on  the  metabolism  of  biologically  active  pep-
ides  than  previously  recognized  [16]. The  two  substrates
sed  most  often  for  measuring  ACE  activity  and  inhibition
n  vitro  —  Hippuryl-His-Leu  and  N-[3-(2-furyl)acryloyl]-L-
henylalanylglycylglycine  (FAPGG)  —  only  have  the  N-termini
locked  and  substrates  with  two  termini  blocked  have  been
eveloped  [22].
iological impact of ACE
CE  was  originally  isolated  in  1956  as  a  ‘hypertensin-
onverting  enzyme’  [35]. In  the  RAS,  ACE  cleaves  the
ecapeptide  Ang  I-(1—10)  (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-
is-Leu)  into  the  octapeptide  Ang  II-(1—8)  by  removing
he  C-terminal  dipeptide  His-Leu.  When  the  RAS  is  over-
ctive,  Ang  II  exerts  its  harmful  effects  primarily  via
he  AT1  receptor,  whereas  the  AT2  receptor  may  oppose
nd  counterbalance  those  effects  mediated  by  AT1  recep-
or  to  exert  protective  actions  [1].  Ang  II  is  a  potent
asoconstrictor,  stimulates  the  release  of  aldosterone  and
ntidiuretic  hormone  or  vasopressin  and  increases  the  reten-oncert  to  raise  blood  pressure.  A  nonapeptide  derivative
f  Ang  I,  des-Asp1-Ang  I-(2—10),  prevents  infarction-related
nd  non-infarction-related  cardiac  injuries  and  disorders.
376  C.  Guang  et  al.
Figure 2. Multiple effector systems of the renin-angiotensin system. ACE: angiotensin-I-converting enzyme; ACE2: angiotensin-I-converting
enzyme 2; AGT: angiotensinogen; AMPA: aminopeptidase A; AMPM: aminopeptidase A; Ang I: angiotensin I; Ang II: angiotensin II; AT1R:
angiotensin II receptor, type 1; AT2R: angiotensin II receptor, type 2; IRAP: insulin-regulated aminopeptidase; NEP: neutral endopeptidase;
PEP: prolyl endopeptidase.
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cis-Leu  can  be  cleaved  from  the  peptide  by  ACE  to  produce
ng  III-(2—8)  [14], which  has  40%  of  the  vasoconstriction
ctivity  of  Ang  II.  Ang  III  exerts  its  effects,  in  principle,  in  a
imilar  manner  to  Ang  II,  and  may  be  equally  or  even  more
mportant  in  mediating  the  release  of  vasopressin  [1].  ACE
lso  degrades  Ang-(1—9)  to  Ang-(1—7)  then  further  degrades
his  peptide  to  the  inactive  Ang-(1—5)  (Fig.  2).  In  addition,
CE  (also  termed  kininase  II)  inactivates  the  vasodilators
radykinin-(1—9)  (Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg)  and
allidin  (Lys-bradykinin)  in  the  kallikrein-kinin  system,  by
leaving  the  C-terminal  dipeptide  Phe-Arg.  ACE  eventually
leaves  its  primary  metabolite  bradykinin-(1—7)  into  the
horter  fragment  bradykinin-(1—5)  [36].
Through  Ang  II  and  aldosterone,  ACE  may  also  be  impli-
ated  in  the  impairment  of  nitric  oxide  bioavailability  and
ell  oxidative  stress,  augmenting  the  generation  of  reactive
xygen  species  and  peroxynitrite  [37,38].  With  the  ability
o  hydrolyze  neuropeptides  such  as  enkephalin  [39,40],  sub-
trate  P,  neurotensin  [31]  and  LH-RH,  ACE  may  be  involved
n  the  functioning  of  the  brain  and  nervous  system.  ACE
b
d
A
lay affect  the  digestive  system  by  hydrolyzing  the  peptide
ormone  cholecystokinin  and  gastrin  [30]. The  in  vivo  exper-
ment  conducted  by  Azizi  et  al.  [41]  proved  that  acute  ACE
nhibition  could  increase  the  level  of  the  natural  stem  cell
egulator  AcSDKP  in  plasma.  AcSDKP  substantially  inhibits
ell  cycle  entry  of  normal  haematopoietic  stem  cells  and
rotects  haemopoiesis  against  damage  caused  by  cycle-
ctive  cytotoxic  agents  [42]. AcSDKP  can  also  inhibit  the
roliferation  of  hepatocytes  [43]  and  lymphocytes  [44]  and
timulate  angiogenesis  [45]  in  vivo.  The  in  vivo  antiﬁbrotic
ffect  of  ACE  inhibition  is  partially  mediated  by  AcSDKP
46]. ACE  may  also  affect  susceptibility  to  Alzheimer’s  dis-
ase  by  degrading  A  and  preventing  the  accumulation
f  amyloid  plaques  in  vivo  [47]. In  the  brains  of  amyloid
recursor  protein  Swedish  mutation  transgenic  mice,  ACE
onverts  A1—42 to  A1—40 and  degrades  A,  and  chronic  inhi-
ition  of  ACE  with  captopril  enhances  predominant  A1—42
eposition  [48]. However,  through  the  inhibition  of  brain
CE  activity  in  the  A25—35-injected  mice,  perindopril  ame-
iorates  cognitive  impairment  and  may  therefore  have  a
A
t
n
i
d
b
e
t
i
s
r
p
a
o
d
d
t
S
a
R
t
a
d
s
A
A
t
u
r
a
n
p
i
i
a
i
a
d
7
r
i
a
s
A
c
c
C
z
a
2
m
d
h
1
wACE,  ACE2  and  renin  
beneﬁcial  effect  on  Alzheimer’s  disease  as  well  as  hyper-
tension  [49].
ACE inhibitors
Using  the  assumed  mechanistic  analogy  to  other  zinc  metal-
lopeptidases,  plus  the  knowledge  that  several  snake-venom
peptides  potentiate  the  action  of  bradykinin  by  inhibit-
ing  ACE,  efforts  were  undertaken  to  develop  orally-active
peptide  analogues  for  potential  use  in  the  treatment  of
hypertension  [9].  The  ﬁrst  such  compound,  captopril  or  D-
3-mercapto-2-methylpropanoyl-L-proline,  is  an  analogue  of
the  Ala-Pro  sequence,  with  sulphydryl  as  a  strong  chelating
group  for  the  zinc  ion.  Its  adverse  effects,  which  were  the
same  as  those  caused  by  mercapto-containing  penicillamine,
prompted  the  design  of  non-sulphydryl  ACE  inhibitors  [50].
The  results  were  two  active  inhibitors:  enalaprilat  and  lisino-
pril.  They  are  both  essentially  tripeptide  analogues  with
a  zinc-co-ordinating  carboxyl  group  and  a  phenylalanine
that  occupies  the  S1  groove  in  the  enzyme.  Lisinopril  is
a  lysine  analogue  of  enalaprilat  but  it  is  hydrophilic,  with
greater  afﬁnity  than  enalaprilat.  The  later  compounds  are
all  variations  of  the  ﬁrst  three  inhibitors,  with  most  of
the  differences  residing  in  the  functionalities  that  bind  the
active  site  zinc  and  the  S2′ pocket.  In  addition  to  phospho-
nates,  ketones  are  also  useful  as  chelators  [51].
Currently,  there  are  more  than  10  ACE  inhibitors  mar-
keted  that  are  widely  used  as  ﬁrst-line  therapy  for
cardiovascular  diseases,  including  hypertension,  heart  fail-
ure,  heart  attack  and  left  ventricular  dysfunction.  According
to  the  functional  moiety,  they  are  divided  into  three
types:  thiol  (captopril),  carboxylate  (benazepril,  enalapril,
lisinopril,  moexipril,  perindopril,  quinapril,  ramipril,  tran-
dolapril)  or  phosphate  (fosinopril).  Some  ACE  inhibitors  are
now  administrated  clinically  as  ethyl-ester  prodrugs,  which
have  good  bioavailability  but  are  inactive  in  their  own  right.
They  are  then  converted  to  the  active  diacid  molecules
in  vivo  by  esterases.
As a  drug  class,  ACE  inhibitors  are  very  effective,  have  a
relatively  low  incidence  of  side  effects  and  are  well  toler-
ated.  A  common  side  effect  of  ACE  inhibitors  is  a  dry  cough,
which  appears  in  5—20%  of  patients  and  may  result  in  the
discontinuation  of  treatment.  Another  serious  problem  is
angioedema,  which  affects  0.1—0.5%  of  patients  and  can  be
life-threatening.  The  two  side  effects  have  generally  been
attributed  to  altered  concentrations  of  bradykinin  [51]. Use
of  ACE  inhibitors  during  the  second  and  third  trimesters  of
pregnancy  is  contraindicated  because  of  their  association
with  an  increased  risk  of  foetopathy,  a  group  of  conditions
that  includes  oligohydramnios,  intrauterine  growth  retarda-
tion,  hypocalvaria,  renal  dysplasia,  anuria,  renal  failure  and
death.  Exposure  to  ACE  inhibitors  during  the  ﬁrst  trimester
of  pregnancy  may  place  the  infant  at  increased  risk  for  major
congenital  malformations  [52].
The  initial  drug  development  of  clinical  ACE  inhibitors
was  based  on  the  assumption  of  an  active  site  related
to  that  of  carboxypeptidase  A  but  organized  to  remove
a  dipeptide  rather  than  a  single  amino  acid  from  the  C-
terminus  of  its  substrate.  It  is  now  known  that  sACE  has  two
active  sites,  neither  of  which  resembles  that  of  carboxypep-
tidase  A,  and  that  these  sites  are  not  identical.  Clinical
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CE  inhibitors,  however,  show  little  discrimination  between
hese  two  active  sites  [9].  Ang  I  is  hydrolyzed  predomi-
antly  by  the  C  domain  of  sACE  in  vivo  [29]  but  bradykinin
s  hydrolyzed  by  both  active  sites  [53]; therefore  a  C
omain-selective  inhibitor  would  allow  some  degradation  of
radykinin  by  the  N  domain  and  this  degradation  could  be
nough  to  prevent  the  accumulation  of  excess  bradykinin
hat  has  been  observed  during  attacks  of  angioedema.  That
s,  the  C  domain-selective  inhibition  could  possibly  result  in
pecialized  control  of  blood  pressure  with  fewer  vasodilator-
elated  adverse  effects  [51]. A  structure-activity  study  has
roved  that  the  group  substitution  involving  the  phenyl  ring
nd  carbon  chain  at  the  sulphonyl  and  propionyl  moieties
f  captopril  is  essential  for  better  activity  towards  the  C
omain  of  ACE  [54]. There  is  increasing  evidence  that  the  N
omain  of  sACE  is  responsible  for  the  in  vivo  degradation  of
he  natural  haemoregulatory  hormone  AcSDKP  [27,41,55].
o,  N  domain-selective  inhibition  might  open  up  novel  ther-
peutic  areas.  Two  phosphinic  tetrapeptides,  RXPA380  and
XP407,  have  been  found  to  be  highly  selective  inhibitors  of
he  C  and  N  domains  of  sACE,  respectively  [51]. The  avail-
bility  of  the  three-dimensional  structures  of  the  C  and  N
omains  of  sACE  makes  the  structure-based  design  of  active
ite-speciﬁc  inhibitors  possible  [17,18].
CE2
CE2  (EC  3.4.17.-)  is  also  a  type  I  transmembrane  glycopro-
ein  and  its  expression  has  now  been  recognized  as  being
biquitous.  It  appears  to  be  susceptible  to  cleavage  that
eleases  the  catalytical  active  ectodomain.  A  disintegrin
nd  metalloprotease  17  (ADAM17;  also  known  as  tumour
ecrosis  factor-alpha  cleavage  enzyme  [TACE])  is  a  major
rotease  for  soluble  ACE2  shedding,  while  phorbol  ester,
onomycin,  endotoxin  and  the  proinﬂammatory  cytokines
nterleukin-1  and  tumour  necrosis  factor-alpha  can  also
cutely  induce  ectodomain  release  [56]. Calmodulin  bind-
ng  sites  have  been  identiﬁed  in  the  cytoplasmic  tail  of  ACE2
nd  calmodulin  inhibitors  are  proved  to  increase  ACE2  shed-
ing  [57]. The  cleavage  site  resides  between  amino  acids
16  and  741  near  the  predicted  transmembrane  domain  and
esidue  Lys548 in  the  ectodomain  plays  an  important  role
n  dictating  ACE2  ectodomain  shedding  [58]. ACE2  has  805
mino  acids  encoded  from  18  exons  and  shares  about  42%
equence  identity  with  the  N  and  C  domains  of  sACE  [16].
CE2  also  belongs  to  the  M2  family  of  metalloproteases  but
onsists  of  a  single  active  site  domain  that,  by  sequence
omparison,  more  closely  resembles  the  N  domain  than  the
 domain  of  sACE  (Fig.  1)  [11]. In  addition  to  the  conserved
inc  metallopeptidase  consensus  sequence  HEXXH  (amino
cids  374—378),  there  is  a  conserved  glutamate  residue
4  residues  C-terminal  to  the  second  histidine  of  the  zinc
otif,  which  serves  as  the  third  zinc  ligand  [16]. The  three-
imensional  structure  of  a  truncated  extracellular  region  of
uman  ACE2  shows  that  the  active  site  domain  (residues
9—611)  can  be  further  divided  into  two  subdomains  I  and  II,
hich  form  two  sides  of  a  long  deep  cleft  and  are  connected
nly  at  the  ﬂoor  of  the  active  site  cleft  by  a  prominent  -
elix.  The  deeply  recessed  and  shielded  proteolytic  active
ite  of  ACE2  is  a  common  structural  feature  of  proteases
nd  can  avoid  hydrolysis  of  correctly  folded  and  functional
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roteins.  The  zinc  is  co-ordinated  by  His374,  His378,  Glu402
nd  one  water  molecule  in  the  subdomain  I  near  the  bot-
om,  whereas  a  chloride  ion  is  co-ordinated  by  Arg169, Trp477
nd  Lys481 in  the  subdomain  II  [58]. The  ACE2  transmembrane
-terminal  domain  shares  48%  sequence  identity  with  collec-
rin  (Fig.  1),  a  non-catalytic  protein  shown  to  have  a critical
ole  in  amino  acid  reabsorption  in  the  kidney  [59], pancre-
tic  beta  cell  proliferation  and  possibly  insulin  exocytosis
6].
Unlike  sACE  and  gACE,  which  are  primarily  dipep-
idylcarboxypeptidases,  ACE2  functions  predominantly  as
 monocarboxypeptidase,  with  a  substrate  preference  for
ydrolysis  between  proline  and  a  hydrophobic  or  basic  C-
erminal  residue  [6].  It  is  like  carboxypeptidase  A  in  its
ction  model  but  is  different  in  active  structure  because  the
atter  has  an  HXXE  zinc-binding  motif  with  the  third  ligand
histidine)  positioned  108—135  residues  further  towards  the
-terminus  [16]. ACE2  efﬁciently  cleaves  a  single  residue
henylalanine  from  Ang  II  to  generate  Ang-(1—7),  with
bout  400-fold  higher  catalytic  efﬁciency  than  the  conver-
ion  of  Ang  I  to  Ang-(1—9)  by  removing  the  C-terminal
eucine  residue  (Fig.  2).  Other  substrates  with  high  catalytic
fﬁciency  are  apelin-13,  dynorphin  A-(1—13)  and  des-Arg9-
radykinin  [60]. Arg514 of  ACE2  has  been  identiﬁed  as  a
esidue  critical  to  substrate  selectivity  [61]. ACE2  activity
s  also  regulated  by  chloride  ions;  it  has  been  proposed  that
hloride  binding  induces  subtle  changes  in  the  conformation
f  the  active  site,  which  either  facilitate  or  hinder  substrate
inding  [6].  For  the  substrate  Ang  I,  ACE2  activity  increases
ith  increased  [Cl−]  and  a  plateau  is  reached  at  approxi-
ately  500  mM  Cl−.  For  the  substrate  Ang  II,  an  increase  in
CE2  activity  is  observed  as  [Cl−]  increases  from  0—100  mM
ut  any  further  increase  in  [Cl−]  decreases  ACE2  activity
ntil  a  plateau  is  reached  at  500  mM  Cl−;  ACE2  activity  at
00  mM  Cl− is  even  lower  than  that  in  the  absence  of  Cl−
0  mM).  Consequently,  an  increase  in  [Cl−]  above  100  mM,
hich  is  the  physiological  concentration  in  human  plasma,
ncreases  Ang  I  and  decreases  Ang  II  cleavage  by  ACE2.  This
as  an  effect  on  the  localized  concentration  of  Ang  II  in
he  kidney,  where  ACE2  has  a  high  level  of  expression  and
xtracellular  chloride  ion  levels  ﬂuctuate.  Thus,  in  vivo  Cl−
ensitivity  may  serve  as  a  homeostatic  regulatory  mecha-
ism  [61]. ACE2  activity  is  unaffected  by  inhibitors  of  ACE
captopril,  lisinopril  and  enalaprilat)  or  carboxypeptidase
 (benzylsuccinate  and  potato  carboxypeptidase  inhibitor)
16].
iological actions of ACE2
he  major  function  of  ACE2  is  to  counter-regulate  ACE
ctivity  by  reducing  Ang  II  bioavailability  and  increasing  Ang-
1—7)  formation.  As  a  result,  ACE2  plays  a  crucial  role  in
aintaining  the  balance  between  the  two  axes  ACE2/Ang-
1—7)/Mas  and  ACE/Ang  II/AT1  of  the  RAS;  a  chronic  and
ustained  imbalance  may  lead  to  pathophysiology  of  the
ardiovascular,  renal,  pulmonary  and  central  nervous  sys-
ems  [62]. Studies  have  shown  that  ACE2  overexpression  and
ecombinant  ACE2  treatment  can  attenuate  hypertension  in
nimal  models  [63,64],  while  in  humans,  there  is  a  strong
ssociation  between  ACE2  polymorphisms  and  hypertension
n  Han  Chinese  [65]. In  addition  to  the  Ang  II  system,  ACE2
a
c
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ay  regulate  blood  pressure  through  other  peptide  systems,
uch  as  bradykinin  and/or  apelin  [6].  ACE2  gene  delivery
66]  and  ACE-(1—7)  infusion  [67]  also  have  beneﬁcial  effects
n  atherosclerosis,  whereas  ACE2  deﬁciency  accentuates
ascular  atherosclerosis  and  inﬂammation  [67]  in  animal
odels.  Regarding  heart  function,  ACE2  null  mice  display
mpaired  cardiac  contractility  [68]  and  the  loss  of  ACE2
n  wild-type  mice  accelerates  adverse  ventricular  remod-
lling  by  potentiation  of  Ang  II  effects  by  means  of  the  AT1
eceptors  [69]. Ang-(1—7),  through  interaction  with  the  Mas
eceptor,  can  improve  atrial  tachyarrhythmias  [70], myocar-
ial  performance,  cardiac  modelling  and  survival  [3,6]  in
odent  heart  failure  models.  In  humans,  ACE2  gene  vari-
nts  might  be  involved  in  modulation  of  left  ventricular
ass  in  men  [71]  and  soluble  ACE2  activity  is  increased  in
atients  with  heart  failure  and  correlates  with  disease  sever-
ty  to  exert  cardioprotective  actions  [72]. Deletion  of  the
CE2  gene  in  mice  leads  to  the  development  of  glomeru-
osclerosis  and  increased  albuminuria  [73], while  treatment
ith  the  ACE2  inhibitor  MLN4760  can  worsen  renal  dam-
ge  in  streptozotocin-induced  diabetic  mice  [74]. Chronic
reatment  with  Ang-(1—7)  improves  renal  endothelial  dys-
unction  via  the  Mas  receptor  in  apolipoprotein  E-deﬁcient
ice,  by  increasing  levels  of  endogenous  nitric  oxide  [75],
hereas  genetic  deletion  of  the  Mas  receptor  in  mice
eads  to  a  reduction  in  urine  volume,  sodium  retention,
icroalbuminuria  and  reduced  renal  blood  ﬂow,  which  are
ssociated  with  upregulation  of  the  AT1  receptor  and  trans-
orming  growth  factor-beta  messenger  ribonucleic  acid  [76].
his  evidence  indicates  the  protective  role  of  ACE2/Ang-
1—7)/Mas  in  renal  function.  ACE2  has  also  been  shown  to
egulate  cardiovascular  functions  in  brain  regions.  Overex-
ression  of  ACE2  in  the  rostral  ventrolateral  medulla  reduces
igh  blood  pressure  and  heart  rate  in  spontaneously  hyper-
ensive  rats  (SHRs)  [77]. In  the  nucleus  tractus  solitarius  of
HRs,  ACE2  gene  transfer  improves  baroreceptor  heart  rate
eﬂex  [78]. In  the  mouse  subfornical  organ,  ACE2  overex-
ression  inhibits  AT1  receptor  expression  and  prevents  Ang
I-mediated  pressor  and  drinking  responses  [79]. In  addition,
CE2/Ang-(1—7)/Mas  can  exert  cerebroprotective  functions
n  endothelin-1-induced  ischaemic  stroke  in  rodent  models
80]. ACE2  exerts  a  host  of  actions  on  the  cardiopul-
onary  system,  which  include  prevention  of  endothelial
ysfunction,  reduction  in  pulmonary  oxidative  stress,  atten-
ation  of  vascular  impairment,  anti-inﬂammatory  effects
nd  anticardiac  remodelling  effects.  All  these  properties
re  responsible  for  the  protective  role  of  ACE2  against  pul-
onary  arterial  hypertension  [81].
Structure-based  drug  screening  has  iden-
iﬁed  two  ACE2  activators:  a  xanthenone
1-[(2-diethylamino)ethyl-amino]-4-(hydroxymethyl)-7-
(4-methylphenyl)sulphonyloxy]-9H-xanthene-9-one;  XNT)
nd  resorcinolnaphthalein.  XNT  hydrogen  bonds  with  ACE2
esidues  Lys94,  Tyr196,  Gly205 and  His 195,  and  resorcinolnaph-
halein  is  involved  in  three  hydrogen  bonds  with  residues
ln98, Gln101 and  Gly205.  XNT  and  resorcinolnaphthalein
odulate  ACE2  activity  possibly  by  two  mechanisms.
ogically,  the  closed  conformation  of  the  enzyme  cannot
llow  the  substrate  into  its  active  site.  In  the  presence  of
ompound,  the  free  enzyme  may  be  shifted  to  the  open
orm,  effectively  increasing  the  activity  coefﬁcient  of  the
nzyme.  Alternatively,  product  release  is  a rate-limiting
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step  in  ACE2  turnover.  ACE2  activity  may  be  enhanced  in
the  presence  of  compound,  as  the  enzyme-product  complex
empties  more  quickly  and  ACE2  becomes  available  to  start
another  cycle.  XNT  and  resorcinolnaphthalein  enhance  in
vitro  ACE2  activity  in  a  dose-dependent  manner  and  show
no  signiﬁcant  effects  on  ACE  activity.  Administration  of
XNT  to  SHRs  can  result  in  a  decrease  in  blood  pressure,
improvements  in  cardiac  function  and  reversal  of  myocar-
dial,  perivascular  and  renal  ﬁbrosis  [82]. The  protective
role  of  XNT  against  hypertension-induced  cardiac  ﬁbrosis  is
associated  with  activation  of  ACE2,  increases  in  Ang-(1—7)
and  inhibition  of  extracellular  signal-regulated  kinases  [83].
Furthermore,  ACE2  activation  by  XNT  attenuates  thrombus
formation  and  reduces  platelet  attachment  to  vessels
[84]. XNT  also  prevents  pulmonary  vascular  remodelling
and  right  ventricular  hypertrophy  and  ﬁbrosis  in  a  rat
model  of  monocrotaline-induced  pulmonary  hypertension
[85]. Development  of  XNT  is  being  pursued  to  translate
the  vasoprotective  concept  of  ACE2  into  an  effective
cardiovascular  therapy  [62]. Diminazine  aceturate,  a
small  molecule  antiprotozoal  agent  that  shares  structural
similarity  with  XNT,  has  recently  been  demonstrated  to
be  a  potent  activator  of  ACE2  and  to  decrease  mean
arterial  pressure  and  myocardial  ﬁbrosis  in  SHRs  [86].
Intracerebroventricular  infusion  of  diminazine  aceturate,
prior  to  and  following  endothelin-1-induced  middle  cerebral
artery  occlusion,  signiﬁcantly  attenuates  cerebral  infarct
size  and  neurological  deﬁcits  in  a  rat  model  [80]. These
data  suggest  that  diminazine  aceturate  may  serve  as  a
lead  compound  for  the  discovery  of  the  next  generation
of  drugs  for  the  treatment  of  cardiovascular  disease  and
hypertension  [86].
Interestingly,  peptidase-independent  actions  of  ACE2
have  also  been  elucidated.  ACE2  has  been  identiﬁed  as  an
essential  receptor  for  the  coronavirus  (CoV)  that  causes
severe  acute  respiratory  syndrome  (SARS).  The  spike  pro-
tein  of  SARS-CoV  attaches  the  virus  to  its  cellular  receptor
ACE2  with  a  binding  domain  on  the  spike  protein  mediating
the  interaction  [87]. This  ACE2-spike  interaction  leads  to
endocytosis  of  virus  particles  through  internalization  with
ACE2,  induces  the  fusion  of  virus  with  host  cells  and  estab-
lishes  SARS-CoV  infection  with  the  release  of  viral  RNAs  into
cytoplasm  [6].  The  spike  protein  of  SARS-CoV  also  induces
TACE-dependent  shedding  of  the  ACE2  ectodomain,  with
the  involvement  of  the  ACE2  cytoplasmic  domain.  Cellu-
lar  TACE  and  the  ACE2  cytoplasmic  tail  promote  viral  entry
and  infection.  These  observations  indicate  that  ACE2  shed-
ding  and  its  causative  cellular  signals  may  be  attributable  to
SARS-CoV-induced  tissue  damage  [88]. An  ACE2  inhibitor,  N-
(2-aminoethyl)-1  aziridine-ethanamine,  has  been  identiﬁed
as  being  effective  in  blocking  SARS-CoV  spike  protein-
mediated  cell  fusion  [89]. The  SARS-CoV  receptor  function
of  ACE2  is  independent  of  its  catalytic  activities  for  Ang
II  degradation  but  ACE2-mediated  Ang  II  degradation  is
still  important  for  lung  protection  from  SARS  pathogene-
sis  [6,90]. So,  the  consequence  of  long-term  activation  of
ACE2  must  be  determined  and  the  effects  of  ACE2  acti-
vators  on  the  immune  competence  of  animals  and  their
vulnerability  to  SARS-CoV  infection  must  be  tested  before
these  molecules  are  ready  for  preclinical  trials  [64]. ACE2
is  also  the  receptor  for  the  human  coronavirus  NL63  that
was  discovered  in  2004  in  the  Netherlands  and  was  shown
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o  be  globally  distributed  [91]. Additionally,  due  to  the  high
omology  with  collectrin  at  its  transmembrane,  ACE2  binds
o  B0AT1-family  amino  acid  transporters  and  contributes  to
he  absorption  of  neutral  amino  acids  in  animal  intestines
6,92].  Thus,  ACE2  may  be  involved  in  multiple  biological
unctions.
enin, prorenin and the (pro)renin
eceptor
enin  (EC  3.4.23.15)  is  a  key  enzyme  of  the  RAS.  Since  its
iscovery  100  years  ago,  an  impressive  quantity  of  infor-
ation  about  renin  has  been  compiled.  It  is  generally
ccepted  that  the  active  renin  found  in  the  circulation
f  mammals  almost  exclusively  originates  from  the  kid-
ey.  In  addition  to  systemic  renin,  there  are  a  number  of
xtrarenal  tissues  that  express  renin  as  part  of  the  local
r  tissue-speciﬁc  RASs.  Within  the  kidney,  renin  is  predom-
nantly  produced  by  the  juxtaglomerular  cells.  (Pro)renin
ene  transcription  in  these  cells  is  controlled  through  several
echanisms,  among  which  cyclic  adenosine  monophos-
hate  (cAMP)/protein  kinase  A/cAMP  response  element
inding  protein  (stimulatory)  and  calcium/protein  kinase  C
inhibitory)  cascades  are  employed  by  physiological  cues,
hereas  signal  transducers,  activators  of  transcription  and
uclear  factor  B  transcription  factors  (inhibitory)  and  mem-
ers  of  the  nuclear  receptor  superfamily  probably  become
elevant  in  pathological  situations.  Prorenin  is  stored  in  vesi-
les,  activated  to  renin  and  then  released  upon  demand.
he  release  of  renin  is  under  the  control  of  the  intracellular
AMP  (stimulatory),  Ca2+ (inhibitory)  and  cyclic  guanosine
onophosphate  signalling  pathways.  Meanwhile,  a  great
umber  of  intrarenally  generated  or  systemically  acting
actors  have  been  identiﬁed  that  control  renin  secretion
irectly  at  the  level  of  renin-producing  cells,  by  activat-
ng  the  cAMP  or  Ca2+ signalling  pathways  [93]. Renin  is  an
spartyl  protease  with  a  typical  structure  made  of  two  lobes.
he  cleft  between  the  lobes  contains  the  active  site,  charac-
erized  by  two  catalytic  aspartic  residues.  Renin  is  a  highly
peciﬁc  enzyme  and  has  only  one  known  substrate  (AGT)
94].
Prorenin  is  the  ‘inactive’  precursor  of  renin.  In  addi-
ion  to  the  main  organ,  the  kidney,  other  tissues,  such
s  the  brain,  the  adrenal  gland,  the  submandibular  gland,
he  glands  of  the  reproductive  system  and  adipose  tissue,
re  also  able  to  secrete  prorenin  in  the  surrounding  milieu
nd  in  plasma.  In  contrast  to  renin,  prorenin  is  released
onstitutively;  renin  and  prorenin  levels  are  usually  well
orrelated.  Under  some  physiopathological  circumstances,
uch  as  pregnancy  and  diabetes,  prorenin  levels  exceed
y  far  those  of  renin  [94]. Prorenin  has  a prosegment
f  43  amino  acid  residues  attached  to  the  N-terminus  of
ature  renin;  the  prosegment  folds  into  an  active  site
left  of  mature  renin  to  prevent  catalytic  interaction  with
GT  [95]. Prorenin-renin  conversion  occurs  in  the  kidney
efore  renin  is  released  from  the  juxtaglomerular  cells.
everal  enzymes,  including  proconvertase  1  and  cathep-
in  B,  have  been  proposed  to  be  responsible  for  this
rreversible  cleavage  of  the  prosegment  from  prorenin  to
orm  mature  renin.  A  (reversible)  non-proteolytic  activa-
ion  of  prorenin  may  also  occur.  At  acidic  pH  and/or  low
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duration  of  action,  weak  antihypertensive  activity  and  high80  
emperature,  prorenin  is  capable  of  undergoing  a  confor-
ational  change,  involving  the  unfolding  of  the  proseg-
ent  from  the  enzymatic  cleft.  This  non-proteolytically-
ctivated  prorenin  is  fully  enzymatically  active  [96].
nder  physiological  conditions,  approximately  2%  of  plasma
rorenin  is  in  the  open  form  and  can  also  display  enzymatic
ctivity  [94].
The  traditional  assumptions  of  renin  being  just  an  enzyme
esponsible  for  the  cleavage  of  AGT  and  prorenin  being  just
n  ‘inactive’  proenzyme  were  challenged  by  the  cloning
f  a  human  (P)RR  in  2002  [94]. The  (P)RR  is  a  single
ransmembrane-domain  protein  of  350  amino  acids,  with
 large  unglycosylated  and  highly  hydrophobic  N-terminal
omain  responsible  for  renin  and  prorenin  binding  and  a
hort  cytoplasmic  tail  of  about  20  amino  acids  involved  in
ntracellular  signalling  [97]. The  (P)RR  was  ﬁrst  identiﬁed
n  cultured  human  mesangial  cells  and  bound  well  to  renin
nd  prorenin  with  a  KD in  the  nanomolar  range  [96]. Bind-
ng  of  prorenin  induced  a  conformational  change  in  the
olecule,  increasing  its  enzymatic  activity  from  virtually
ero  to  values  similar  to  those  of  active  renin  in  solution
ithout  proteolytic  removal  of  the  prosegment  [93,98].  Two
egions  in  the  human  prorenin  segment,  namely  T7PFKR10P
a  gate  that  is  not  accessible  by  its  speciﬁc  antibodies  until
t  is  loosened  from  the  active  site  cleft)  and  I11PFLKR15P
a  handle,  a  protruding  pentameric  segment),  have  been
dentiﬁed  as  being  crucial  for  the  non-proteolytic  activa-
ion  [99]. Renin  bound  to  the  (P)RR  displays  a  3-  to  5-fold
ncrease  in  the  catalytic  efﬁciency  of  AGT  conversion  to
ng  I  compared  with  free  renin  [97,100].  In  addition  to
he  Ang-dependent  function  on  the  cell  surface  related  to
he  increased  catalytic  activity  of  receptor-bound  (pro)renin
renin  activity  of  activated  prorenin  and  increased  activity
f  renin)  that  leads  to  the  formation  of  Ang  I  from  AGT,
he  (P)RR  system  also  has  Ang-independent  intracellular
ffects  that  are  not  necessarily  related  to  the  RAS  [7].  Patho-
ogical  conditions  like  high  blood  pressure  upregulate  the
eceptor,  whereas  elevated  (pro)renin  concentrations  down-
egulate  the  receptor  via  translocation  of  the  transcription
actor  promyelotic  zinc  ﬁnger  protein  to  the  nucleus  [98]. In
he  Ang-independent  signalling  pathways,  prorenin-induced
ctivation  of  mitogen-activated  protein  kinase  p38  and  sub-
equent  phosphorylation  of  heat  shock  protein  27  result  in
ctin  polymerization,  while  (pro)renin-induced  activation
f  the  extracellular  signal-regulated  kinase  1/2  (p44/p42)
ignalling  cascade  leads  to  the  intracellular  expression  of
roﬁbrotic  genes,  giving  rise  to  the  synthesis  of  transforming
rowth  factor-,  plasminogen  activator  inhibitor-1,  colla-
en  1  and  ﬁbronectin.  These  effects  potentially  increase
ardiac  and  renal  hypertrophy  and  ﬁbrosis  [97,101—103].
he  discovery  of  the  (P)RR  has  conﬁrmed  the  hypothesis
hat  renin  is  also  a  hormone.  It  has  been  suggested  that
locking  the  (P)RR  may  be  a  new  target  for  renal  and
ardiac  end-organ  protection  [1].  Additionally,  the  mannose-
-phosphate/insulin-like  growth  factor  II  receptor  can  bind
oth  renin  and  prorenin  with  high  afﬁnity  and  is  believed
o  serve  as  a  clearance  receptor  for  renin/prorenin.  An
ntracellular  renin-binding  protein  has  been  also  cloned
nd  found  to  be  an  inhibitor  of  renin  activity  but  its
eletion  affected  neither  blood  pressure  nor  plasma  renin
94].
c
e
rC.  Guang  et  al.
Pro)renin receptor antagonist and renin
nhibitors
fter  the  discovery  of  the  receptor,  a  (P)RR  antagonist  was
esigned,  based  on  the  idea  that  the  prosegment  contains  a
andle  region  that  binds  to  the  receptor,  allowing  prorenin
o  become  catalytically  active  in  a  non-proteolytic  manner
96].  The  antagonist  (also  known  as  hand  region  peptide,
RP),  consisting  of  10  amino  acids  (NH2-RILLKKMPSV-COOH),
esembles  the  handle  region  (I11PLLKK15P)  of  rat  prorenin
rosegment  and  will  thus  competitively  bind  to  the  (P)RR
s  a  decoy  peptide  and  inhibit  the  receptor-mediated  acti-
ation  of  prorenin  [95]. Treatment  with  the  HRP  in  diabetic
ice  and  rats  decreased  the  renal  content  of  Ang  I and  II  and
nhibited  the  development  of  nephropathy  without  affecting
yperglycaemia  [104,105].  In  stroke-prone  SHRs,  continuous
ubcutaneous  administration  of  the  HRP  inhibited  activa-
ion  of  the  tissue  RAS  without  affecting  the  circulating  RAS
r  arterial  pressure  and  signiﬁcantly  attenuated  the  devel-
pment  and  progression  of  proteinuria,  glomerulosclerosis
nd  cardiac  ﬁbrosis  [106,107].  Infusion  of  the  HRP  in  human
P)RR  transgenic  rats  signiﬁcantly  inhibited  the  develop-
ent  of  glomerulosclerosis,  proteinuria,  mitogen-activated
rotein  kinase  activation  and  transforming  growth  factor-
expression  in  the  kidneys  [108]. Future  research  should
e  able  to  determine  to  what  degree  the  beneﬁcial  in  vivo
ffects  of  HRP  are  due  to  prorenin  blockade  [98]  and  are
elated  to  interference  with  renin  binding  and  the  RAS  [4].
ecoy  effects  of  the  HRP,  however,  were  not  conﬁrmed  by
ther  research  groups  [109—112].
ACE  inhibitors  and  AT1  receptor  blockers  (ARBs)  are
roven  to  be  effective  therapeutic  agents  in  the  treatment
f  CVD.  However,  both  ACE  inhibitors  and  ARBs  lead  to  a  sub-
tantial  compensatory  rise  in  circulating  active  renin  and
ng  peptides  that  may  eventually  limit  their  therapeutic
otential  [113]. Moreover,  the  increased  Ang  I seen  with
CE  inhibitors  can  subsequently  be  converted  to  Ang  II  by
on-ACE  pathways,  mediated  by  chymase  and  chymotrypsin-
ike  Ang-generating  enzyme  [114]. In  addition  to  the  side
ffects  of  ACE  inhibitors,  such  as  cough  and  angioedema,  a
eta-analysis  of  randomized  controlled  trials  in  2010  sug-
ested  that  ARBs  are  associated  with  a  modestly  increased
isk  of  new  cancer  diagnosis,  although  conclusions  about  the
xact  risk  of  cancer  associated  with  each  particular  drug
ave  not  been  drawn  [115]. Based  on  this  study,  the  United
tates  Food  and  Drug  Administration  is  conducting  a  review
o  assess  the  possible  link  between  the  use  of  ARBs  and  can-
er.  Therefore,  direct  renin  inhibition  may  be  an  alternative
harmacological  approach  to  RAS  inhibition.
Renin  is  the  rate-limiting  step  of  the  RAS  and  the  concept
f  blocking  the  RAS  at  its  origin  by  inhibiting  renin  has
xisted  for  at  least  50  years  [113]. The  ﬁrst-generation  renin
nhibitors  were  peptide  analogues  of  AGT  and  the  second-
eneration  compounds  were  peptidomimetic  agents  that  are
ipeptide  transition-state  analogue  inhibitors  of  the  active
ite.  But  these  renin  inhibitors  had  limited  clinical  use  due
o  poor  metabolic  stability  and  oral  bioavailability,  shortost  of  synthesis  [114]. A  combination  of  molecular  mod-
lling  and  X-ray  crystallographic  analysis  of  the  active  site  of
enin  led  to  the  development  of  aliskiren,  a  new  non-peptide
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low-molecular-weight  orally-active  renin  inhibitor.  Aliskiren
has  a  high  binding  afﬁnity  for  renin  and  appears  to  bind  to
both  the  hydrophobic  S1-/S3-binding  pocket  and  a  large,
distinct  subpocket  that  extends  from  the  S3-binding  site
toward  the  hydrophobic  core  of  the  enzyme.  Aliskiren  is
a  potent  competitive  inhibitor  of  renin  but  very  poorly
inhibits  related  aspartic  peptidases.  It  shows  no  effects
on  cytochrome  P450  isoenzyme  activities  and  is  not  bound
extensively  to  blood  proteins,  therefore  having  a  low
potential  for  drug  interactions  [113]. Compared  with  the
earlier  renin  inhibitors,  aliskiren  is  more  resistant  to  intesti-
nal  degradation  and  possesses  signiﬁcantly  improved  oral
bioavailability.  The  terminal  half-life  ranges  from  23  to
40  hours,  which  makes  it  suitable  for  once-daily  dosing.
Aliskiren  monotherapy  displays  an  antihypertensive  efﬁcacy
similar  if  not  superior  to  that  of  other  ﬁrst-line  antihy-
pertensive  drugs,  with  a  safety  and  tolerability  proﬁle
similar  to  that  of  ARBs.  Combined  with  various  antihyper-
tensive  agents,  aliskiren  exhibits  synergistic  effects  [114].
From  2007,  aliskiren  was  approved  by  regulatory  bod-
ies  in  both  Europe  and  the  United  States,  for  use  alone
and  with  other  agents  in  the  treatment  of  hypertension
[113].  Recent  studies  showed  that  aliskiren  treatment  also
markedly  increased  the  plasma  concentration  of  (pro)renin
in  patients  and  failed  to  inhibit  the  non-catalytic  effects  of
(pro)renin  [110,116].  The  pharmaceutical  company  Novartis
reported  that  the  addition  of  aliskiren  to  standard  ther-
apy  for  patients  recovering  from  a  heart  attack  did  not
provide  the  anticipated  effect  of  limiting  adverse  changes
to  the  heart’s  left  ventricle.  In  December  2011,  Novartis
announced  the  early  termination  of  the  Aliskiren  Trial  in
Type  2  Diabetes  Using  Cardio-Renal  Endpoints  (ALTITUDE)
and  advised  that  aliskiren  should  not  be  used  in  combina-
tion  with  ACE  inhibitors  or  ARBs  in  patients  with  diabetes.
The  study  was  conducted  in  type  2  diabetic  patients  at
high  risk  of  fatal  and  non-fatal  cardiovascular  and  renal
events;  aliskiren  300  mg  was  given  in  addition  to  an  ACE
inhibitor  or  an  ARB.  The  overseeing  Data  Monitoring  Com-
mittee  concluded  that  study  patients  were  unlikely  to
beneﬁt  from  aliskiren  and  that  there  was  a  higher  inci-
dence  of  adverse  events  related  to  non-fatal  stroke,  renal
complications,  hyperkalaemia  and  hypotension  in  this  high-
risk  population  after  18—24  months  of  combined  therapy
(www.novartis.com).  Aliskiren  has  been  shown  to  be  a  very
safe  antihypertensive  after  more  than  20,000  patient-years
of  data.  However,  as  we  have  seen  in  Ongoing  Telmisar-
tan  Alone  and  in  combination  with  Ramipril  Global  Endpoint
Trial  (ONTARGET)  that  the  combination  of  telmisartan  (an
ARB)  and  ramipril  (an  ACE  inhibitor)  is  associated  with  more
adverse  events  without  an  increase  in  beneﬁt  in  patients
with  vascular  disease  or  high-risk  diabetes  without  heart
failure  [117], the  combination  of  multiple  safe  drugs  in  this
class  may  no  longer  be  a  promising  strategy.
Future directions of bioactives from
natural  plant and/or food resources for
RAS regulation
Over  the  last  decade,  a  number  of  food-derived  com-
pounds  have  been  shown  to  have  in  vitro  ACE  inhibitory
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ctivity.  Some  of  them  display  signiﬁcant  antihypertensive
ctivity  in  rats  and  humans.  Among  these  compounds,  food-
erived  ACE  inhibitory  peptides  have  been  most  widely
tudied  [14,118].  A  quantitative  structure-activity  relation-
hip  study  indicated  that  a  potent  ACE  inhibitory  dipeptide
hould  have  a  large  and  hydrophobic  amino  acid  at  the
-terminus  and  a  non-polar  amino  acid  or  possibly  a  posi-
ively  charged  amino  acid  at  the  N-terminus.  For  tripeptides,
he  most  favourable  residues  for  the  C-terminus  are  aro-
atic  amino  acids,  while  hydrophobic  amino  acids  are
referred  for  the  N-terminus  and  positively  charged  amino
cids  are  preferred  for  the  middle  position  [119]. The
n  vitro  half-maximal  inhibitory  concentration  (IC50)  values
f  food-derived  ACE  inhibitory  peptides  are  about  1000-
old  higher  than  that  of  synthetic  captopril  but  they  have
igher  in  vivo  activities  than  would  be  expected  from  their
n  vitro  activities.  It  has  been  suggested  that  food-derived
eptides  might  act  via  different  antihypertensive  mech-
nisms,  possess  higher  afﬁnities  for  tissues  and  be  more
lowly  eliminated  than  synthetic  captopril  [118]. Until  now,
nly  two  lactotripeptides  (VPP  and  IPP)  have  been  success-
ully  commercialized.  Data  from  van  Mierlo  et  al.,  however,
id  not  support  a  blood  pressure-lowering  effect  of  the
wo  tripeptides  in  Caucasians  [120]. Given  the  discrepancy
etween  in  vivo  and  in  vitro  results,  further  investigation
nto  the  in  vivo  and  clinical  antihypertensive  effects  and
echanisms  of  food-derived  ACE  inhibitors  is  necessary.
hree  dipeptides  (IR,  KF  and  EF)  in  pea  protein  hydrolate
ave  been  identiﬁed  as  inhibiting  renin  activity  in  vitro
121].  Oleic  acid  and  linoleic  acid  isolated  from  rice  and
ome  cereals  also  have  in  vitro  renin  inhibitory  activity
122,123].  A  series  of  studies  have  shown  that  saponins
rom  different  food/plant  sources,  primarily  from  soybean,
an  inhibit  in  vitro  renin  activity  [124—127];  among  them,
rally  administered  soybean  saponin  can  lead  to  a reduc-
ion  of  blood  pressure  in  SHRs  but  the  direct  evidence  for
aponin  suppressing  plasma  renin  activity  in  vivo  is  still
acking  [124]. Experiments  are  required  to  further  inves-
igate  the  biochemical  and  biological  properties  of  these
lant/food-derived  non-peptides  that  are  related  to  renin
nhibition.  Signiﬁcant  conceptual  progress  made  in  the  last
ew  years  leads  us  to  conclude  that  ACE2  could  serve  as
 new  direction  for  improved  therapeutics  for  cardiovas-
ular  disease.  Compared  with  ACE  inhibitor  therapy,  ACE2
s  an  endogenous  regulator  of  the  RAS.  Targeting  ACE2
ould  not  only  produce  the  vasoprotective/antiproliferative
eptide  Ang-(1—7)  but  would  also  inﬂuence  the  vasocon-
trictive/proliferative  effects  of  the  ACE/Ang  II/AT1  axis.  As
 part  of  the  vasoprotective/antiproliferative  axis,  ACE2  can
ffectively  control  ﬁbrosis  and  structural  remodelling  and
s  extremely  beneﬁcial  for  pulmonary  hypertension.  ACE2
ctivation  may  provide  improved  protection  and  reversal  of
schaemia-induced  neural  damage.  Thus,  direct  activation
f  ACE2  could  result  in  better  outcomes  in  cardiovascu-
ar  disease.  Additionally,  ACE2  is  a  multifunctional  enzyme
ith  many  biologically  active  substrates.  The  effects  of
CE2  on  substrates  other  than  Ang  I  and  Ang  II  may  hold
elevance  for  the  treatment  of  cardiovascular  disease  [62].
NT  analogues  exist  in  many  natural  plant  resources  and
ave  shown  various  physiological  functions.  Using  these
esources  to  search  for  in  vitro  ACE2  activators  would  be  a
ood  starting  point  for  developing  plant  food-derived  ACE2
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ctivating  agents.  Ongoing  experiments  would  characterize
hese  ACE2  activators.  Compared  with  RAS  regulatory  drugs,
hese  plant/food-derived  bioactives  appear  more  natural
nd  safer  to  the  consumer.  As  part  of  a  daily  diet,  bioactives
rom  food  sources  may  result  in  a  much  lower  healthcare
ost.  Plant/food-derived  RAS  regulators  could  be  applied  in
he  prevention  of  hypertension  and  as  initial  treatment  in
ildly  hypertensive  individuals  [118].
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